The Clear Cell Squamous Cell Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Clear Cell Squamous Cell Carcinoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Clear Cell Squamous Cell Carcinoma . Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Clear Cell Squamous Cell Carcinoma and features dormant and discontinued products.
GlobalData tracks five drugs in development for Clear Cell Squamous Cell Carcinoma by four companies/universities/institutes. The top development phase for Clear Cell Squamous Cell Carcinoma is phase ii with three drugs in that stage. The Clear Cell Squamous Cell Carcinoma pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Clear Cell Squamous Cell Carcinoma pipeline products market are: Pfizer, Simcere Pharmaceutical Group and Sorrento Therapeutics.
The key targets in the Clear Cell Squamous Cell Carcinoma pipeline products market include ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1), Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF/SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1), and Growth Factor Receptor Bound Protein 2 (Adapter Protein GRB2 or SH2/SH3 Adapter GRB2 or Protein Ash or GRB2).
The key mechanisms of action in the Clear Cell Squamous Cell Carcinoma pipeline product include Tubulin Inhibitor with one drug in Phase I. The Clear Cell Squamous Cell Carcinoma pipeline products include four routes of administration with the top ROA being Intravenous and three key molecule types in the Clear Cell Squamous Cell Carcinoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Clear Cell Squamous Cell Carcinoma overview
Clear cell squamous cell carcinoma (SCC), or hydropic SCC, is an extremely rare variant of SCC. It may be caused by ultraviolet radiation. It is usually not life-threatening, but if left untreated, it can grow large or spread to other parts of the body. Symptoms include a rough, reddish, scaly area; a dome-shaped or wart-like growth; a new sore or raised area on an old scar or sore; and pain in the throat, mouth, or ear. Physical examination and biopsy can be helpful for diagnosis. Surgery, cryotherapy, photodynamic therapy, topical chemotherapy, chemotherapy, and targeted therapy are the treatment options.
For a complete picture of Clear Cell Squamous Cell Carcinoma ‘s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
